Dr. Clay B. Siegall is known as the man who co-founded Seattle Genetics, a company that is focused on developing and innovating drugs that are used in fighting cancer. His passion for helping patients and his leadership skills has led the company to develop the ADCs (antibody-drug conjugates). In 2011, he led his company to secure the FDA approval of ADCETRIS®, which was its first ADC product.
ADCETRIS® has been doing well in the market due to the collaboration with other notable companies in the industry like Takeda Pharmaceutical Company has enabled the drug to hit the global market. It has received approval in more than 65 countries.
Seattle Genetics has also partnered with other international companies and licensed its ADC technologies to companies like Pfizer which has generated over $350 million in revenue up to date. Its ADC technology has enabled the development of more than twenty ADCs which are still in clinical trials.
Dr. Siegall played a crucial part in leading the company through its funding process, where it was able to raise over $1.2 billion in private and public funding, including its successful IPO in 2001.
He said that his passion for helping cancer patients is what led to the formation of Seattle Genetics. He grew up watching his father battling cancer, and this experience made him aware just how unprepared oncologists are in their fight against cancer.
Dr. Siegall has worked in the cancer research industry for a relatively extended period. He currently serves as a member of the board of Ultragenyx Pharmaceutical, Washington Roundtable, and Alder BioPharmaceuticals.
His contribution to the cancer research has led him to be awarded numerous awards including the 2012 “Pacific Northwest Ernst & Young Entrepreneur of the Year.” He also received the Alumnus of the Year for Computer, Natural Science, and Math award from the University of Maryland in 2013. He has written more than seventy papers and holds over fifteen patents. He earned his Ph.D. from the George Washington University.